Nuveen LLC Makes New $313,000 Investment in Enanta Pharmaceuticals, Inc. $ENTA

Nuveen LLC acquired a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 56,671 shares of the biotechnology company’s stock, valued at approximately $313,000.

Several other institutional investors have also recently bought and sold shares of the business. Invesco Ltd. raised its holdings in Enanta Pharmaceuticals by 29.3% during the first quarter. Invesco Ltd. now owns 60,277 shares of the biotechnology company’s stock worth $333,000 after buying an additional 13,663 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Enanta Pharmaceuticals by 23.7% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 30,465 shares of the biotechnology company’s stock worth $168,000 after buying an additional 5,829 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Enanta Pharmaceuticals by 3.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 159,801 shares of the biotechnology company’s stock worth $882,000 after buying an additional 4,974 shares during the last quarter. US Bancorp DE acquired a new position in Enanta Pharmaceuticals during the first quarter worth $36,000. Finally, XTX Topco Ltd acquired a new position in Enanta Pharmaceuticals during the first quarter worth $110,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on ENTA shares. Westpark Capital started coverage on shares of Enanta Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $24.00 target price for the company. HC Wainwright started coverage on shares of Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a “buy” rating and a $20.00 target price for the company. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. Finally, JMP Securities increased their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a report on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $22.25.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $8.85 on Friday. The firm has a market cap of $189.21 million, a P/E ratio of -2.05 and a beta of 0.84. The firm has a 50-day moving average of $7.77 and a 200 day moving average of $6.79. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $13.37.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.40. The company had revenue of $18.31 million during the quarter, compared to analyst estimates of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. Equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.